J. Zhang

Merck & Co., Inc., Rahway, NJ, USA (United States) ORCID: 0000-0001-9639-4056

2

h-index

2

Publications

229

Citations

Publications

2 shown

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee , David C. Turner , Enriqueta Felip +20 more

2016 Annals of Oncology 157 citations

Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

Edward B. Garon , Leena Gandhi , Naiyer A. Rizvi +17 more

2014 Annals of Oncology 72 citations

Frequent Co-Authors

Manash Chatterjee

Merck & Co., Inc., Rahway, NJ, USA (United States)

David C. Turner

Merck & Co., Inc., Rahway, NJ, USA (United States)

Enriqueta Felip

Vall d'Hebron Institute of Oncology

H. Léna

Centre Hospitalier Universitaire de Rennes

Federico Cappuzzo

Azienda Unità Sanitaria Locale Della Romagna

Leora Horn

Vanderbilt University Medical Center

Researcher Info

h-index: 2
Publications: 2
Citations: 229
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-9639-4056

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.